Karin Hardt | Director Clinical Development, Scientist
Johnson & Johnson Innovation

Karin Hardt, Ph.D. in Biochemistry and MSc in Public Health, is a Director in Clinical R&D at J&J, with expertise in prophylactic vaccine development. She currently contributes to the development of a vaccine for the prevention of invasive Escherichia coli disease and previously served as Medical Lead for the COVID-19 vaccine program. Before joining J&J, she spent 20 years at GSK Vaccines, where she held the role of Clinical R&D Director and contributed to the development and market introduction of multiple bacterial and viral vaccines. Karin has also held academic teaching responsibilities at the Université Catholique de Louvain-La-Neuve and the Université Libre de Bruxelles in Belgium, covering pharmacovigilance, clinical studies, and drug development.